5
Participants
Start Date
February 18, 2015
Primary Completion Date
March 6, 2018
Study Completion Date
April 3, 2018
Nilotinib
Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib was not dosed by weight or body surface area. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.
Ruxolitinib
Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
Novartis Investigative Site, Berlin
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Jena
Novartis Investigative Site, Leipzig
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY